General Health

Nystrom & Associates Names Experienced Behavioral Health Leader, Mark Peterson, CEO

Retrieved on: 
Friday, January 13, 2023
General Health, Mental Health, Other Health, Health, Telemedicine, Virtual Medicine, Nautic Partners, Pharmacist, Mental health, Peterson, Growth, Medicine, Management, Nystrom

Nystrom & Associates (“Nystrom”) today announced Mark Peterson, RPh, as its new CEO.

Key Points: 
  • Nystrom & Associates (“Nystrom”) today announced Mark Peterson, RPh, as its new CEO.
  • The company also employs over 1,000 behavioral health providers with broad clinical expertise across its 50 outpatient clinics.
  • Prior to that, he was CEO of Genoa Healthcare, an organization that has partnered with Nystrom for over 13 years to provide behavioral health pharmacy services in several of its clinics.
  • “As a founder of Genoa, Mark built a mission-driven organization serving those living with behavioral health issues,” Nystrom said.

UK Healthcare Markets and Care Markets Subscription 2023: Comprehensive, Reliable and Independent Reporting on Healthcare - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Health, General Health, Dentistry, News, Office for National Statistics, Human, PDF, Name, Intelligence, Publication, Health insurance, Medicine

The "UK Healthcare Markets and Care Markets (with digital archive)" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UK Healthcare Markets and Care Markets (with digital archive)" newsletter has been added to ResearchAndMarkets.com's offering.
  • Healthcare Markets and Care Markets deliver comprehensive, reliable and independent reporting across the full spectrum of independent healthcare covering acute and primary healthcare services and social care.
  • These news journals jointly cover community care, older care, specialist care, medical and surgical hospitals and clinics, psychiatric hospitals, dentistry, primary healthcare and temporary/flexible staffing.
  • The publisher is the chosen provider of independent sector healthcare market data to the UK government's Office for National Statistics.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, January 13, 2023
Health, Genetics, General Health, Clinical Trials, Research, Science, Biotechnology, David Berry (inventor), Calendar, Therapy, RSU, Employment, Compensation, Financial adviser

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 4,500 shares of its common stock.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 4,500 shares of its common stock.
  • These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Seres’ board of directors in December 2022.

AHF Eswatini Commemorates 15th Year with New Centre of Excellence!

Retrieved on: 
Friday, January 13, 2023
Oncology, AIDS, Philanthropy, Health, Foundation, General Health, Pharmaceutical, Local-level governments of Papua New Guinea, AIDS Healthcare Foundation, TB, Population Services International, Entrepreneurship, Education, AIDS, HIV, Matsapha, Medicine, Government, Ministry, Center of excellence, Cervical cancer, Kingdom, Georgetown University, MOH, FLAS, Partnership, Pharmacy, Woman, Growth, Patient, HIV/AIDS, AHF, Ministry of Health (Saudi Arabia), SZL, PSI, Member, ART, Multimedia, Watts Labor Community Action Committee, Pharmaceutical industry, Medical device

View the full release here: https://www.businesswire.com/news/home/20230112005861/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005861/en/
    As part of its commemoration of 15 years in the country, AHF Eswatini will unveil its newly constructed state-of-the-art LaMvelase Centre of Excellence in partnership with the Manzini City Council on Jan. 13.
  • (Photo: Business Wire)
    As part of its commemoration, AHF Eswatini will unveil its newly constructed state-of-the-art LaMvelase Centre of Excellence in partnership with the Manzini City Council (who provided the land on which the clinic sits).
  • Although providing treatment was AHF Eswatini’s foremost priority, it has attained much more in over a decade.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

EDP Biotech Announces New Hire Sam Libby to Lead Rapid Company Growth and Expansion Opportunities

Retrieved on: 
Thursday, January 12, 2023
Technology, Research, Other Technology, Biotechnology, Health, General Health, Other Science, Science, Oncology, Disease, EDP, Corporate development, Philosophy, Growth, Mergers and acquisitions, Acquisition, Investment, Knowledge, Financial services, Perfume

EDP Biotech proudly welcomes Sam Libby as the Company's Head of Mergers & Acquisitions and Corporate Development.

Key Points: 
  • EDP Biotech proudly welcomes Sam Libby as the Company's Head of Mergers & Acquisitions and Corporate Development.
  • Libby will manage investments, drive merger and acquisition opportunities and develop corporate relationships for the Company.
  • Additionally, Libby will support the execution and expansion of our strategy as the Company is meeting milestones faster than expected and is experiencing rapid growth.
  • These are values deeply shared by EDP Biotech," said Eric Mayer, CEO of EDP Biotech.

Expansion of AESARA Europe with the Appointment of Italian pharmaceutical industry veteran, Patrizia Berto

Retrieved on: 
Thursday, January 12, 2023
Health Technology, Health Insurance, Clinical Trials, Cardiology, Surgery, Biotechnology, Alternative Medicine, AIDS, Other Science, Health, Research, Science, Nursing, Other Health, FDA, Diabetes, Managed Care, Pharmaceutical, General Health, Optical, Oncology, Mental Health, Medical Devices, Hospitals, Genetics, Strategic partnership, HTA, GlaxoSmithKline, MBA, University, Management

AESARA ( www.aesara.com ) is delighted to announce the appointment of industry veteran value & access strategist Patrizia Berto PharmD, MBA, to the European Strategic Partnerships team.

Key Points: 
  • AESARA ( www.aesara.com ) is delighted to announce the appointment of industry veteran value & access strategist Patrizia Berto PharmD, MBA, to the European Strategic Partnerships team.
  • Based in Italy, within the AESARA Europe team, Patrizia will bring: depth of insight into the Italian market; a broader European perspective on health technology assessment (HTA), pricing & reimbursement; and globally-applicable technical expertise in health economics and outcomes research (HEOR).
  • Gavin Outteridge, Managing Director of AESARA Europe said, “I am thrilled to be able to connect Patrizia to AESARA’s clients.
  • I hope to teach some, to learn a lot and to put all my experience at the service of AESARA’s clients,” said Patrizia Berto on her appointment as Principal, AESARA Europe.

Insights on the Advanced Wound Care Global Market to 2027 - Rising Prevalence of Pressure Ulcers, Diabetic Foot Ulcers and Other Chronic Wounds Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Biotechnology, Managed Care, Medical Supplies, Surgery, General Health, Health, Diabetes, Hospitals, Infection, Gel, Organ transplantation, Tissue, COVID-19, 3D ultrasound, Wilford Hall Ambulatory Surgical Center, Silver, Burns, Elective surgery, Ulcer, Growth, Prevalence, Diabetes, Urology, Organic acid, Pain management, Obesity, Pharmaceutical industry, Dentistry

Advanced wound care is a standard medical solution that provides specialized treatment for chronic infections and non-healing wounds by removing dead and inflamed tissues.

Key Points: 
  • Advanced wound care is a standard medical solution that provides specialized treatment for chronic infections and non-healing wounds by removing dead and inflamed tissues.
  • It includes medications, equipment, and several products that help treat acute and chronic wounds, such as burns, ulcers, and post-operative wounds.
  • Advanced wound care products comprising silver and alginates are extensively used to remove excess fluids from wounds and protect them from infections.
  • The increasing global geriatric population and the rising prevalence of pressure ulcers, diabetic foot ulcers, and other chronic wounds are among the key factors positively influencing the market.

Prahlad Singh Appointed to Board of Directors of Amphenol Corporation

Retrieved on: 
Thursday, January 12, 2023
Mobile, Wireless, Networks, General Health, Hardware, Technology, Defense, Semiconductor, Government Technology, Automotive Manufacturing, Aerospace, Manufacturing, Health, Business administration, DuPont (1802–2017), PerkinElmer, Master of Business Administration, University, Publication, Corporation, GE Healthcare, Philips, NYSE, Research, PKI, Chemistry, Doctor of Philosophy, Management, Northeastern University, Amphenol

Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol’s board of directors.

Key Points: 
  • Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol’s board of directors.
  • Dr. Singh is currently the President and Chief Executive Officer of PerkinElmer (NYSE: PKI) and brings more than twenty-five years of global leadership experience to Amphenol’s board.
  • He was promoted to President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and was appointed to its board of directors in 2019.
  • “Prahlad brings a wealth of experience to Amphenol, and we are excited to welcome him to Amphenol’s board of directors,” said R. Adam Norwitt, Amphenol’s President and CEO.

Sleep Apnea Devices Global Market Report 2023: Emergence of Artificial Intelligence in Sleep Apnea Treatment Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
General Health, Health, Medical Devices, Artificial intelligence, PAT, Ageing, Obstructive sleep apnea, Pulse oximetry, American Academy of Sleep Medicine, Sleep apnea, Pressure, Respiratory system, ResMed, OSA, Safety, CPAP, Actigraphy, AASM, Risk, Diagnosis, Patient, Prevalence, HST, Night, AHI, American Academy, PSG, Noise, Pharmaceutical industry, Medical device

The "Sleep Apnea Devices Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleep Apnea Devices Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global sleep apnea devices market is expected to grow at a CAGR of 7.07% during 2022-2027.
  • The growing sleep apnea devices market is attributed to factors such as the high prevalence of sleep apnea, increasing potential risk factors, technological advancements in sleep apnea devices, and an increasingly aging population.
  • Artificial intelligence (AI) will pave the way for screening and diagnosing OSA, reduce costly PSG deployment, and streamline the path to effective treatment in the sleep apnea devices market.

Allergy Diagnostics Global Market Report 2022: Rising Air Pollution Fuels Rapid Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
General Health, Health, Other Health, Allergen, Allergy, World Health Organization, Analyser, Product-service system, Hazelnut, WHO, Allergic rhinitis, ELISA, Air pollution, Patient, LGC, NML, Alexander Kapp (dermatologist and allergist), MHealth, Asthma, Milk, Medical device

According to the report, 'Allergy Diagnostics Market,' the allergy diagnostics market size was valued at $5 billion in 2021, and is estimated to reach $16.7 billion by 2031, growing at a CAGR of 13.2% from 2022 to 2031.

Key Points: 
  • According to the report, 'Allergy Diagnostics Market,' the allergy diagnostics market size was valued at $5 billion in 2021, and is estimated to reach $16.7 billion by 2031, growing at a CAGR of 13.2% from 2022 to 2031.
  • The global market for allergy diagnostics is expanding dramatically, mostly as a result of rising air pollution that can lead to chronic respiratory illnesses.
  • In addition, several studies have shown a connection between air pollution and allergic rhinitis, asthma, and other conditions, which is fueling the expansion of the allergy diagnostics market growth.
  • Due to the rapid expansion of the global allergy diagnostics industry, researchers and scientists have accelerated their R&D efforts to create cutting-edge technological gadgets for better allergy diagnostic usage on mobile phones.